Susquehanna International Group
OVID icon

Susquehanna International Group’s Ovid Therapeutics OVID Stock Holding History

Susquehanna International Group’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.32M Buy
1,947,594
+1,605,854
+470% +$2.87M ﹤0.01% 4506
2025
Q4 		$557K Sell
341,740
-247,354
-42% -$381K ﹤0.01% 8521
2025
Q3 		$766K Buy
589,094
+358,849
+156% +$311K ﹤0.01% 7978
2025
Q2 		$76K Buy
230,245
+147,161
+177% +$44.3K ﹤0.01% 11936
2025
Q1 		$25.9K Buy
83,084
+37,964
+84% +$23.3K ﹤0.01% 12052
2024
Q4 		$42.1K Buy
+45,120
New +$50.5K ﹤0.01% 11746
2024
Q1 		– Sell
-22,220
Closed -$71.5K – 13020
2023
Q4 		$71.5K Buy
+22,220
New +$76K ﹤0.01% 11538
2023
Q3 		– Sell
-16,958
Closed -$55.6K – 12703
2023
Q2 		$55.6K Sell
16,958
-146,808
-90% -$499K ﹤0.01% 11295
2023
Q1 		$423K Buy
163,766
+151,717
+1,259% +$360K ﹤0.01% 8980
2022
Q4 		$22.4K Buy
+12,049
New +$20.5K ﹤0.01% 11729
2022
Q2 		– Sell
-307,874
Closed -$744K – 13652
2022
Q1 		$967K Buy
307,874
+21,504
+8% +$67.6K ﹤0.01% 7210
2021
Q4 		$919K Buy
286,370
+89,105
+45% +$305K ﹤0.01% 7525
2021
Q3 		$663K Buy
197,265
+90,545
+85% +$330K ﹤0.01% 8654
2021
Q2 		$417K Sell
106,720
-79,883
-43% -$315K ﹤0.01% 10021
2021
Q1 		$750K Buy
186,603
+23,444
+14% +$77.9K ﹤0.01% 8465
2020
Q4 		$377K Buy
163,159
+133,279
+446% +$621K ﹤0.01% 8843
2020
Q3 		$172K Sell
29,880
-40,403
-57% -$270K ﹤0.01% 9592
2020
Q2 		$518K Sell
70,283
-235,419
-77% -$1.1M ﹤0.01% 7292
2020
Q1 		$911K Buy
305,702
+189,367
+163% +$638K ﹤0.01% 5622
2019
Q4 		$483K Buy
+116,335
New +$367K ﹤0.01% 7052

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Susquehanna International Group's OVID Position: Q1 2026 in Review

Susquehanna International Group increased its Ovid Therapeutics (OVID) stake by 470% in Q1 2026, buying an estimated $2.87M and bringing the position to 1,947,594 shares worth $4.32M. The position accounts for ﹤0.01% of the portfolio, ranked #4506.

Susquehanna International Group first reported a position in OVID in Q4 2019 and has held it in 20 quarters since. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

  • Susquehanna International Group held 1,947,594 shares of Ovid Therapeutics worth $4.32M as of Q1 2026.
  • Susquehanna International Group bought 1,605,854 Ovid Therapeutics shares in Q1 2026, an estimated $2.87M.
  • Ovid Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #4506 holding.
  • Susquehanna International Group first reported a position in Ovid Therapeutics in Q4 2019 and has held it in 20 quarters since.
  • 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.